Safety of Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors for Advanced NSCLC. Pierre C, Goter T, Lena H, Le Guen Y, et al. J Thorac Oncol 2023;18:e14-e16.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Pierre C, Goter T, Lena H, Le Guen Y, et al. Safety of Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors for Advanced NSCLC. J Thorac Oncol 2023;18:e14-e16.
PMID: 36682842